Management ranges from altered surgical and adjuvant approaches for women with BRCA1 and BRCA2 mutations, to enhanced surveillance for women with mutations in moderate-penetrance breast cancer genes or in genes associated with risk of other types of cancer [12]. The gene discussed is BRCA2; the disease is cancer.